Sampre Nutritions to Trade Ex-Split and Ex-Bonus on November 14; Last day to buy shares today
By Shishta Dutta | Updated at: Nov 13, 2025 11:34 AM IST

Key Corporate Actions
Sampre Nutritions would trade ex-date on November 14, 2025, for two major corporate actions, namely a 1:2 stock split and a 1:1 bonus issue. Investors holding shares as of the record date would be eligible for both the benefits.
Details of the Actions
- Stock Split: The face value of each equity share is going to be reduced from Rs 10 to Rs 5, thus doubling the number of shares in circulation for each shareholder.
- Bonus Issue: The shareholders will be allotted 1 additional share for each one share held, thereby increasing the value of total holdings.
What This Means for Investors
These two simultaneous corporate actions will double the total number of shares held by investors without changing the overall value of their investment. For instance, an investor holding 100 shares prior to bonus would hold 200 shares after the bonus and, following the stock split, each of those shares would have a face value of Rs 5.
A combined effect of increasing liquidity, often making the stock more affordable and improving retail participation.
Stock Performance Summary
Shares of Sampre Nutritions have been on a strong rally for the last several months, rallying over 460 percent in the last six months and over 120 percent year-to-date.
Last Day to Buy To be eligible for the bonus as well as the split, investors need to buy shares before the ex-date on November 14. Any trades executed on or after the ex-date will not carry entitlement to these benefits.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations

